Induction of effective anti-cancer immunity generally requires that mature antigen presenting cells efficiently present tumor antigens in the form of peptides to CD8+ T lymphocytes through major histocompatibility complex (MHC) Class I molecules and to CD4+ T lymphocytes through MHC Class II molecules. Here, CD8A is linked to neoplasm.